Zura Bio Ltd 8-K

What Happened
Zura Bio Ltd (NASDAQ: ZURA) filed a Form 8-K reporting that director Neil Graham resigned effective February 21, 2026 (not due to any disagreement with the company). On the same date the board appointed Dr. Mark Eisner (age 61) and Dr. Ajay Nirula (age 58) as directors. The company also issued a related press release on February 23, 2026. Both new directors bring senior biopharma R&D and clinical development experience (Dr. Eisner most recently CMO at Vir Biotechnology; Dr. Nirula most recently EVP & Head R&D at Recludix Pharma, with prior senior roles at Lilly, Amgen and Biogen).

Key Details

• Neil Graham resigned effective February 21, 2026; resignation not due to disagreement with the company.
• Drs. Mark Eisner and Ajay Nirula were appointed effective February 21, 2026 and will serve until the next annual general meeting or until successors qualify.
• Each new director will receive a prorated annual cash retainer of $40,000 and an initial option grant to purchase the lesser of 51,000 Class A ordinary shares or an option with an option value not exceeding $200,000.
• Option vesting: initial grants vest in 12 equal monthly installments over one year, with any remaining unvested portion vesting the day before the next annual meeting; future annual option grants follow similar terms (first annual grant prorated).

Why It Matters
Board changes are material for investors because new directors influence oversight of strategy and clinical development. Zura’s additions are seasoned drug-development executives, signaling strengthened clinical and R&D expertise at the board level. Compensation is primarily equity-based (with a modest cash retainer), aligning the new directors’ interests with shareholders. The filing also included a press release making the appointments public; the resignation was explicitly not due to any disagreement, which reduces potential governance concerns.